ARTICLE | Company News
Schering gets another HRT non-approvable letter
October 18, 2002 7:00 AM UTC
Schering (FSE:SCH; SHR) received a non-approvable letter from FDA for its Angeliq oral once-daily estradiol and drospirenone HRT therapy to treat menopausal symptoms. SHR would not discuss the content...